menu
    • menu
    [{"orgOrder":0,"company":"University of Georgia","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"SBFM-PL4","moa":"PLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Georgia \/ Sunshine Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"University of Georgia \/ Sunshine Biopharma"},{"orgOrder":0,"company":"University of Georgia","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"SBFM-PL4","moa":"PLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Georgia \/ Sunshine Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"University of Georgia \/ Sunshine Biopharma"},{"orgOrder":0,"company":"University of Georgia","sponsor":"EpiVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Georgia \/ EpiVax","highestDevelopmentStatusID":"4","companyTruncated":"University of Georgia \/ EpiVax"},{"orgOrder":0,"company":"University of Georgia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Georgia \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"University of Georgia \/ Undisclosed"},{"orgOrder":0,"company":"University of Georgia","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"AN15368","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Georgia \/ AN2 Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"University of Georgia \/ AN2 Therapeutics"},{"orgOrder":0,"company":"University of Georgia","sponsor":"National Cottonseed Products Association | Cotton Incorporated | University of Georgia Obesity Initiative","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Cottonseed Oil","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"University of Georgia \/ National Cottonseed Products Association | Cotton Incorporated | University of Georgia Obesity Initiative","highestDevelopmentStatusID":"1","companyTruncated":"University of Georgia \/ National Cottonseed Products Association | Cotton Incorporated | University of Georgia Obesity Initiative"},{"orgOrder":0,"company":"University of Georgia","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"PDS0202","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Georgia \/ PDS Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"University of Georgia \/ PDS Biotechnology"},{"orgOrder":0,"company":"University of Georgia","sponsor":"ZeaVision, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Zeaxanthin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"University of Georgia \/ ZeaVision, LLC","highestDevelopmentStatusID":"1","companyTruncated":"University of Georgia \/ ZeaVision, LLC"},{"orgOrder":0,"company":"University of Georgia","sponsor":"Abbott Laboratories | Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Georgia \/ Abbott Laboratories | Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"University of Georgia \/ Abbott Laboratories | Royal DSM"},{"orgOrder":0,"company":"University of Georgia","sponsor":"CEL-SCI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Georgia \/ CEL-SCI","highestDevelopmentStatusID":"1","companyTruncated":"University of Georgia \/ CEL-SCI"}]

    Find Clinical Drug Pipeline Developments & Deals by University of Georgia

    Menu

    University of Georgia

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AN15368

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : AN2 Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel B...

                            Details : The agreement aims to advance the development of AN2-502998 (formerly known as AN15368), a boron-based small molecule therapeutic under development for the treatment of Chagas disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 18, 2023

                            Lead Product(s) : AN15368

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : AN2 Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PDS0202

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : PDS Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Unive...

                            Details : Under new agreement with the University of Georgia, the novel COBRA antigens are to be used in combination with Versamune® for PDS0202 for the universal prevention of infection by multiple strains of influenza virus.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 01, 2021

                            Lead Product(s) : PDS0202

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : PDS Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SBFM-PL4

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Sunshine Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Signs Exclusive License Agreement with University of Georgia for Covid-19 Compounds

                            Details : Sunshine Biopharma has signed a license agreement with the University of Georgia for two Anti-Covid compounds which UGA had previously developed and patented. Sunshine Biopharma and UGA will advance the development of these two compounds in parallel with...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 04, 2021

                            Lead Product(s) : SBFM-PL4

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Sunshine Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SBFM-PL4

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Sunshine Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sunshine Biopharma and University Of Georgia Team Up To Develop A New Anti-Coronavirus Drug

                            Details : The goal of this cutting-edge collaboration is to develop SBFM-PL4, a protease inhibitor, as a treatment for Coronavirus infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 19, 2020

                            Lead Product(s) : SBFM-PL4

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Sunshine Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cottonseed Oil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : National Cottonseed Products Association | Cotton Incorporated | University of Georgia Obesity Initiative

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oil Consumption and Cholesterol

                            Details : Cottonseed Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypercholesterolemia.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            May 21, 2020

                            Lead Product(s) : Cottonseed Oil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : National Cottonseed Products Association | Cotton Incorporated | University of Georgia Obesity Initiative

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            University of Georgia’s Covid-19 vaccine shows promise in test models

                            Details : The vaccines consist of engineered strains of the parainfluenza virus 5 (PIV5), responsible for kennel cough in dogs.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 21, 2020

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : CEL-SCI

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CEL-SCI to Develop LEAPS COVID-19 Immunotherapy in Collaboration with University of Georgia Center

                            Details : Initial studies with COVID-19 corona virus aim to replicate prior successful preclinical experiments of LEAPS against H1N1pandemic flu in mice conducted with NIAID.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 23, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : CEL-SCI

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : EpiVax

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            EpiVax partners with UGA researcher on Covid-19 vaccine

                            Details : EpiVax has already applied their vaccine reengineering approach to Avian influenza (H7N9) in an NIH funded program with UGA, and UMASS Medical School to address pandemic preparedness.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 04, 2020

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : EpiVax

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Abbott Laboratories | Royal DSM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effects of a Carotenoid Intervention on Cognitive Function

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Cognitive Dysfunction.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 30, 2013

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Abbott Laboratories | Royal DSM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            University of Georgia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zeaxanthin

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : ZeaVision, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effects of a Zeaxanthin Intervention on Visuomotor Function

                            Details : Zeaxanthin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            December 20, 2013

                            Lead Product(s) : Zeaxanthin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : ZeaVision, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth